Compare AbbVie Inc (ABBV) vs iShares MSCI Canada (TSX) (EWC) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

EWC, the iShares MSCI Canada ETF, trades at $61.30, up 0.99% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The fund faces headwinds from renewed U.S.-Canada trade tensions, including 50% tariffs announced in July 2026, though bullish analyst views highlight resilience due to energy and potash exclusions. Key financial ratios are unavailable in the provided data.

Outlook is mixed: technical strength supports near-term gains, but trade policy risks and overbought conditions warrant caution. Investment appeal hinges on Canada's resource-heavy economy navigating tariffs, with diversification benefits for U.S. investors. Risks include escalated trade war impacts on Canadian exports and market volatility.